Ontology highlight
ABSTRACT:
SUBMITTER: Takezawa K
PROVIDER: S-EPMC3473100 | biostudies-literature | 2012 Oct
REPOSITORIES: biostudies-literature
Cancer discovery 20120905 10
EGF receptor (EGFR)-mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKI). The combination of EGFR-TKI afatinib and anti-EGFR antibody cetuximab can overcome acquired resistance in mouse models and human patients. Because afatinib is also a potent HER2 inhibitor, we investigated the role of HER2 in EGFR-mutant tumor cells. We show in vitro and in vivo that afatinib plus cetuximab significantly inhibits HER2 phosphorylation. HER2 overexpression or ...[more]